HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Human epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer is a breast cancer subtype characterized by high aggressiveness, high frequency of brain metastases and poor prognosis. HER-2, a glycoprotein belonging to the ErbB receptor family, is overexpressed on the outer membrane of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/10/2424 |
| _version_ | 1797501060463460352 |
|---|---|
| author | Leopoldo Sitia Marta Sevieri Lorena Signati Arianna Bonizzi Arianna Chesi Francesco Mainini Fabio Corsi Serena Mazzucchelli |
| author_facet | Leopoldo Sitia Marta Sevieri Lorena Signati Arianna Bonizzi Arianna Chesi Francesco Mainini Fabio Corsi Serena Mazzucchelli |
| author_sort | Leopoldo Sitia |
| collection | DOAJ |
| description | Human epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer is a breast cancer subtype characterized by high aggressiveness, high frequency of brain metastases and poor prognosis. HER-2, a glycoprotein belonging to the ErbB receptor family, is overexpressed on the outer membrane of cancer cells and has been an important therapeutic target for the development of targeted drugs, such as the monoclonal antibodies trastuzumab and pertuzumab. These therapies have been available in clinics for more than twenty years. However, despite the initial enthusiasm, a major issue emerged limiting HER-2 targeted therapy efficacy, i.e., the evolution of drug resistance, which could be tackled by nanotechnology. The aim of this review is to provide a first critical update on the different types of HER-2-targeted nanoparticles that have been proposed in the literature in the last decade for therapeutic purposes. We focus on the different targeting strategies that have been explored, their relative outcomes and current limitations that still need to be improved. Then, we review the nanotools developed as diagnostic kits, focusing on the most recent techniques, which allow accurate quantification of HER-2 levels in tissues, with the aim of promoting more personalized medicinal approaches in patients. |
| first_indexed | 2024-03-10T03:12:54Z |
| format | Article |
| id | doaj.art-b1e9c3beaca64e5b9b048ea9f961a9f9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T03:12:54Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b1e9c3beaca64e5b9b048ea9f961a9f92023-11-23T10:22:57ZengMDPI AGCancers2072-66942022-05-011410242410.3390/cancers14102424HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and TreatmentLeopoldo Sitia0Marta Sevieri1Lorena Signati2Arianna Bonizzi3Arianna Chesi4Francesco Mainini5Fabio Corsi6Serena Mazzucchelli7Dipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyDipartimento di Scienze Biomediche e Cliniche, Università di Milano, 20157 Milano, ItalyHuman epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer is a breast cancer subtype characterized by high aggressiveness, high frequency of brain metastases and poor prognosis. HER-2, a glycoprotein belonging to the ErbB receptor family, is overexpressed on the outer membrane of cancer cells and has been an important therapeutic target for the development of targeted drugs, such as the monoclonal antibodies trastuzumab and pertuzumab. These therapies have been available in clinics for more than twenty years. However, despite the initial enthusiasm, a major issue emerged limiting HER-2 targeted therapy efficacy, i.e., the evolution of drug resistance, which could be tackled by nanotechnology. The aim of this review is to provide a first critical update on the different types of HER-2-targeted nanoparticles that have been proposed in the literature in the last decade for therapeutic purposes. We focus on the different targeting strategies that have been explored, their relative outcomes and current limitations that still need to be improved. Then, we review the nanotools developed as diagnostic kits, focusing on the most recent techniques, which allow accurate quantification of HER-2 levels in tissues, with the aim of promoting more personalized medicinal approaches in patients.https://www.mdpi.com/2072-6694/14/10/2424nanoparticleHER-2-positive breast cancer |
| spellingShingle | Leopoldo Sitia Marta Sevieri Lorena Signati Arianna Bonizzi Arianna Chesi Francesco Mainini Fabio Corsi Serena Mazzucchelli HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment Cancers nanoparticle HER-2-positive breast cancer |
| title | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment |
| title_full | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment |
| title_fullStr | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment |
| title_full_unstemmed | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment |
| title_short | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment |
| title_sort | her 2 targeted nanoparticles for breast cancer diagnosis and treatment |
| topic | nanoparticle HER-2-positive breast cancer |
| url | https://www.mdpi.com/2072-6694/14/10/2424 |
| work_keys_str_mv | AT leopoldositia her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT martasevieri her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT lorenasignati her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT ariannabonizzi her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT ariannachesi her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT francescomainini her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT fabiocorsi her2targetednanoparticlesforbreastcancerdiagnosisandtreatment AT serenamazzucchelli her2targetednanoparticlesforbreastcancerdiagnosisandtreatment |